Core Viewpoint - The article discusses the dilemma faced by technology and biotech companies in balancing financial data disclosure for investors with the need to protect confidential clinical trial data and core technologies, especially in light of the upcoming 2025 revision of the Data Security Law and the corresponding compliance requirements from the China Securities Regulatory Commission [1] Group 1: Definition and Unique Positioning of "Equity-Confidentiality Integration" - "Equity-Confidentiality Integration" refers to embedding mechanisms for protecting trade secrets within the equity structure design of a company, achieving a dynamic balance between compliance with information disclosure and confidentiality of core assets [1] - The service is characterized by a "three-dimensional integration" approach, focusing on equity, contract, and process levels to ensure confidentiality while facilitating investment [2] Group 2: Differences from Traditional Legal Services - Traditional equity structure services aim for stability and tax optimization, while "Equity-Confidentiality Integration" focuses on balancing compliance disclosure with confidentiality protection [3] - The traditional service often ends after the completion of the equity structure, whereas the new service covers the entire financing cycle with dynamic adjustments [4] Group 3: Service Features of "Equity-Confidentiality Integration" - The service innovatively integrates trade secret protection into the entire equity design process, employing a three-layer protection logic [5] - It offers customized solutions for different stages of technology innovation enterprises, including packages for startups that address control rights and confidentiality agreements [6] Group 4: Target Audience for "Equity-Confidentiality Integration" - The service is particularly suitable for technology innovation companies in the financing stage, allowing them to manage information disclosure risks during due diligence [8] - High-growth companies needing to optimize their equity structure can benefit from the service, which transforms trade secrets into measurable equity assets [9] - Companies with significant R&D investments can leverage the service to enhance data access control and reduce the risk of data leakage [10] Group 5: Implementation Process of "Equity-Confidentiality Integration" - The initial phase involves a diagnostic assessment of the company's trade secrets and equity structure, requiring foundational documents for analysis [11] - The service includes professional drafting and review of legal documents, ensuring that confidentiality clauses are integrated into company bylaws [12] - Ongoing legal risk management is provided, including quarterly compliance reviews and adjustments to the equity structure as needed [13] Group 6: Evaluation of "Equity-Confidentiality Integration" - The service has shown to reduce sensitive information exposure risks by an average of 37% and enhance the valuation of core technologies by 25% for companies that adopt it [15][16] - It is particularly beneficial for technology-driven startups and companies planning multiple financing rounds, as well as those operating across borders facing dual compliance challenges [17]